BiomeBank Develops Pioneering Microbiome Treatments

The MTPConnect Podcast

It’s World Antimicrobial Awareness Week and we are shining a light on Australia’s expertise and innovations to fight superbugs.

In this episode, hosts Caroline Duell and Dr Rebecca Tunstall, MTPConnect’s Senior Director of Stakeholder Engagement, catch up with BiomeBank, a company out of South Australia. As Australia's first public stool bank and a microbial therapeutics company, it is pioneering new treatments for debilitating bowel conditions.

Biomebank Chief Executive Officer Thomas Mitchell, who has worked with key microbiome biotech companies in US and UK, discusses microbiome science – a hot spot in biotechnology right now. The Company currently supplies hospitals with FMT (feacal transplants) to treat patients with hard-to-treat gut infection C. difficile, and is involved with clinical trials treating constipation symptoms linked to Parkinson’s Disease.
We cover BiomeBank’s pipeline of second-generation microbial therapies, setting up Australia’s first GMP facility for the manufacturing of microbial therapies and how the company is collaborating with groups around Australia to improve treatments for patients with unmet needs.